TOWA Pharmaceutical Reports Parent Company's FY26 Results

TOKYO, Jun 24 (Pulse News Wire) – Towa Pharmaceutical CO.,LTD. (4553.T) disclosed the fiscal year 2026 results of its parent company, Yoshida Office Co., Ltd.

As of March 31, 2026, Yoshida Office had capital of ¥10 million. The company’s representative director, Yoshida Toru, holds concurrent positions as a director at Yoshida Office. The capital structure shows that Towa Pharmaceutical owns 40.85% percent of Yoshida Office’s voting rights as of March 31, 2026. In terms of shareholders, NPO Mecenat/Sport Shinkou Kyoukai holds 73,996 shares representing 26.12%, while individual shareholder Kobayashi Chiri owns 80,500 shares accounting for 28.41%.

Other major shareholders include Yamamoto Emi with 80,500 shares (28.41%) and Yoshida Toru with 16,754 shares (5.91%). Regarding the financial statements, Yoshida Office reported revenue of 1,846,262 thousand yen and operating profit of 1,755,685 thousand yen for the fiscal year ending March 31, 2026. The ordinary profit was 1,832,580 thousand yen, and the net profit was 1,762,273 thousand yen after taxes. For more detailed information, refer to the attached balance sheet and income statement.